Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents

Abstract

Patients taking ARAs and PPIs were also excluded from phase 2 and 3 studies of the HCV regimen containing the NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir (16, 22). Approval of grazoprevir/elbasvir is expected in early 2016; thus, the label recommendations for concomitant ARA use remain unknown. Because ARAs were excluded from phase 3… (More)
DOI: 10.1038/ajg.2016.202

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.